Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously
Clinical Trial Grant
Administered By
Pediatrics, Medical Genetics
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
August 19, 2024
End Date
August 1, 2027
Administered By
Pediatrics, Medical Genetics
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
August 19, 2024
End Date
August 1, 2027